11/18
07:00 am
skye
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
Medium
Report
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
11/14
07:09 am
skye
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor [Yahoo! Finance]
Medium
Report
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor [Yahoo! Finance]
11/14
07:00 am
skye
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Medium
Report
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
11/7
04:01 pm
skye
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
Medium
Report
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
11/4
07:00 am
skye
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
Medium
Report
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
11/1
07:00 am
skye
Skye Bioscience to Announce Third Quarter 2024 Results
Medium
Report
Skye Bioscience to Announce Third Quarter 2024 Results
10/29
07:00 am
skye
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Low
Report
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
10/21
07:00 am
skye
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
Medium
Report
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
9/30
08:15 am
skye
Skye Bioscience, Inc. (NASDAQ: SKYE) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $20.00 price target on the stock.
Low
Report
Skye Bioscience, Inc. (NASDAQ: SKYE) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $20.00 price target on the stock.
9/23
07:00 am
skye
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Medium
Report
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
9/20
02:17 pm
skye
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock.
Medium
Report
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock.
9/20
01:29 pm
skye
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
Low
Report
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
9/10
08:01 am
skye
Skye Bioscience, Inc. (NASDAQ: SKYE) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $15.00 price target on the stock.
Medium
Report
Skye Bioscience, Inc. (NASDAQ: SKYE) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $15.00 price target on the stock.
9/6
11:04 am
skye
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
Low
Report
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
9/3
07:00 am
skye
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
Medium
Report
Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
8/27
08:10 am
skye
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
High
Report
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
8/26
07:00 am
skye
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
High
Report
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
8/23
06:49 pm
skye
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
8/23
06:45 pm
skye
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)